Validation of Tissue Microarray Technology in Breast Carcinoma

By R. Camp, L. Charette, David L. Rimm. Laboratory Investigation, 2000

843 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

X-Tile (2004, result): “Because prior studies have shown that a single core adequately represents the staining pattern of an entire slide, all studies were done with a single sample of each tumor (7, 8).”
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer (2009, neutral): “3/22 28/103 24/162 10-yr (95% CI) 5-y (95% CI) 57 (47-69) 64 (59-70) 79 (76-83)”
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. (2011, background): “Once tissue is properly fixed and embedded in paraffin, antigenicity is well preserved, potentially for decades (41,42).”
Expression of luminal and basal cytokeratins in human breast carcinoma (2004, methodology): “Breast cancer tissue microarrays were prepared as described previously [17–19].”
Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring (2012, background): “A limited number of tissue cores adequately represent protein expression in tumor specimens [15,16].”